Italian study tracks Real-Life impact of MS treatment on relapses, fatigue, and thinking

NCT ID NCT06345157

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is observing how well the medication ofatumumab (brand name Kesimpta) works for people with relapsing-remitting multiple sclerosis (RRMS) in everyday Italian clinics. It will follow 379 adults newly starting this treatment for 12 months to see how it affects their relapse rates, disability, fatigue, thinking skills, and overall quality of life. The goal is to understand the real-world benefits and safety of this treatment outside of a controlled clinical trial.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Ancona, AN, 60126, Italy
Novartis Investigative Site

L’Aquila, AQ, 67100, Italy
Novartis Investigative Site

Bari, BA, 70124, Italy
Novartis Investigative Site

Bergamo, BG, 24127, Italy
Novartis Investigative Site

Chieti, CH, 66100, Italy
Novartis Investigative Site

Catania, CT, 95123, Italy
Novartis Investigative Site

Catanzaro, CZ, 88100, Italy
Novartis Investigative Site

Cona, FE, 44124, Italy
Novartis Investigative Site

Foggia, FG, 71122, Italy
Novartis Investigative Site

Florence, FI, 50134, Italy
Novartis Investigative Site

Genova, GE, 16132, Italy
Novartis Investigative Site

Pozzilli, IS, 86077, Italy
Novartis Investigative Site

Monza, MB, 20900, Italy
Novartis Investigative Site

Palermo, PA, 90127, Italy
Novartis Investigative Site

Pavia, PV, 27100, Italy
Novartis Investigative Site

Ravenna, RA, 48100, Italy
Novartis Investigative Site

Reggio Calabria, RC, 89124, Italy
Novartis Investigative Site

Roma, RM, 00152, Italy
Novartis Investigative Site

Roma, RM, 00168, Italy
Novartis Investigative Site

Roma, RM, 00189, Italy
Novartis Investigative Site

Siena, SI, 53100, Italy
Novartis Investigative Site

Sassari, SS, 07100, Italy
Novartis Investigative Site

Trento, TN, 38122, Italy
Novartis Investigative Site

Orbassano, TO, 10043, Italy
Novartis Investigative Site

Torino, TO, 10126, Italy
Novartis Investigative Site

Treviso, TV, 31100, Italy
Novartis Investigative Site

Udine, UD, 33100, Italy
Novartis Investigative Site

Gallarate, VA, 21013, Italy
Novartis Investigative Site

Vicenza, VI, 36100, Italy
Novartis Investigative Site

Naples, 80131, Italy
Novartis Investigative Site

Naples, 80138, Italy
Novartis Investigative Site

Novara, 28100, Italy

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS, RELAPSING-REMITTING